In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Phibro Animal Health Corp’s stock clocked out at $37.74, up 0.94% from its previous closing price of $37.39. In other words, the price has increased by $0.94 from its previous closing price. On the day, 0.13 million shares were traded. PAHC stock price reached its highest trading level at $37.875 during the session, while it also had its lowest trading level at $37.085.
Ratios:
To gain a deeper understanding of PAHC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 44.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 3.09. In the meantime, Its Debt-to-Equity ratio is 2.52 whereas as Long-Term Debt/Eq ratio is at 2.43.
On June 16, 2025, BNP Paribas Exane Upgraded its rating to Neutral which previously was Underperform but kept the price unchanged to $24.
On September 10, 2024, JP Morgan started tracking the stock assigning a Neutral rating and target price of $22.JP Morgan initiated its Neutral rating on September 10, 2024, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when BENDHEIM JACK sold 5,752 shares for $40.93 per share. The transaction valued at 235,405 led to the insider holds 39,200 shares of the business.
BENDHEIM JACK sold 3,520 shares of PAHC for $141,018 on Dec 08 ’25. The President and CEO now owns 46,240 shares after completing the transaction at $40.06 per share. On Dec 09 ’25, another insider, BENDHEIM JACK, who serves as the President and CEO of the company, sold 1,288 shares for $40.19 each. As a result, the insider received 51,763 and left with 44,952 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PAHC now has a Market Capitalization of 1529738496 and an Enterprise Value of 2232368384. As of this moment, Phibro’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.69, and their Forward P/E ratio for the next fiscal year is 12.51. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.74. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.09 while its Price-to-Book (P/B) ratio in mrq is 4.91. Its current Enterprise Value per Revenue stands at 1.595 whereas that against EBITDA is 10.684.
Stock Price History:
The Beta on a monthly basis for PAHC is 0.77, which has changed by 0.72463095 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, PAHC has reached a high of $46.42, while it has fallen to a 52-week low of $16.16. The 50-Day Moving Average of the stock is -8.85%, while the 200-Day Moving Average is calculated to be 21.40%.
Shares Statistics:
It appears that PAHC traded 293.37K shares on average per day over the past three months and 311950 shares per day over the past ten days. A total of 20.40M shares are outstanding, with a floating share count of 20.30M. Insiders hold about 49.98% of the company’s shares, while institutions hold 48.74% stake in the company. Shares short for PAHC as of 1764288000 were 891226 with a Short Ratio of 3.09, compared to 1761868800 on 929598. Therefore, it implies a Short% of Shares Outstanding of 891226 and a Short% of Float of 5.21.
Dividends & Splits
With its trailing 12-month dividend rate of 0.48, PAHC has a forward annual dividend rate of 0.48. Against a Trailing Annual Dividend Yield of 0.012837657. The stock’s 5-year Average Dividend Yield is 2.65.
Earnings Estimates
The dynamic stock of Phibro Animal Health Corp (PAHC) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.69, with high estimates of $0.71 and low estimates of $0.68.
Analysts are recommending an EPS of between $2.8 and $2.66 for the fiscal current year, implying an average EPS of $2.74. EPS for the following year is $3.02, with 4.0 analysts recommending between $3.08 and $2.91.
Revenue Estimates
In. The current quarter, 3 analysts expect revenue to total $355.64M. It ranges from a high estimate of $365M to a low estimate of $349M. As of. The current estimate, Phibro Animal Health Corp’s year-ago sales were $309.26MFor the next quarter, 3 analysts are estimating revenue of $364.42M. There is a high estimate of $372M for the next quarter, whereas the lowest estimate is $356.84M.
A total of 4 analysts have provided revenue estimates for PAHC’s current fiscal year. The highest revenue estimate was $1.48B, while the lowest revenue estimate was $1.46B, resulting in an average revenue estimate of $1.47B. In the same quarter a year ago, actual revenue was $1.3BBased on 4 analysts’ estimates, the company’s revenue will be $1.51B in the next fiscal year. The high estimate is $1.52B and the low estimate is $1.49B.
